Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099 | Zendy

Valérie Journot | Zendy; Geneviève Chêne | Zendy; N De Castro | Zendy; Corinne Rancinan | Zendy; J.P. Cassuto | Zendy; Catherine Allard | Zendy; J. L. Vildé | Zendy; A Sobel | Zendy; M Garré | Zendy; JeanMichel Molina | Zendy

Open Access

Use of Efavirenz Is Not Associated with a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099

Author(s) -

Valérie Journot,

Geneviève Chêne,

N De Castro,

Corinne Rancinan,

J.P. Cassuto,

Catherine Allard,

J. L. Vildé,

A Sobel,

M Garré,

JeanMichel Molina

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/504323

Subject(s) - medicine , efavirenz , randomized controlled trial , human immunodeficiency virus (hiv) , antiretroviral therapy , family medicine , viral load

Efavirenz (EFV) is a highly active antiretroviral drug, use of which is associated with frequent (although transient) neurosensorial adverse reactions. Whether the use of EFV is associated with the risk of depression or suicide remains controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research